Brian Rini, MD, on Key Practice Changing Abstracts in Prostate Cancer From 2021 ESMO

Video
Conference|European Society for Medical Oncology Congress (ESMO)

Brian Rini, MD, discussed abstracts presented during the 2021 ESMO Congress that will have an immediate impact on prostate cancer.

CancerNetwork® spoke with Brian Rini, MD, chief of clinical trials and professor of medicine at the Vanderbilt-Ingram Cancer Center, about intriguing abstracts presented at the 2021 European Society for Medical Oncology (ESMO) Congress. He mentioned a pair of abstracts in prostate cancer that will impact practice moving forward.

Transcription:

In prostate cancer, there were 2 studies presented that will change practice. One was called PEACE-1 (NCT01957436), which looked at triplet therapy versus doublet therapy in prostate cancer. [The trial compared] 2 different hormonal agents plus chemotherapy versus just 1 hormone agent plus chemotherapy and showed a survival advantage that will absolutely impact practice. And then another in the rising PSA setting, looking at double hormone therapy versus single hormone therapy that also showed great results. I think those will immediately change practice.

Reference

Fizazi K, Charles Galceran J, Foulon S, et al. A phase III trial with a 2x2 factorial design in men with de novel metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1. J Clin Oncol. 2021;39(no. 15_suppl):5000-5000. doi: 10.1200/JCO.2021.39.15_suppl.5000

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Related Content
In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.

Delving Into the Current State of Clinical Practice in SCLC

Roman Fabbricatore
December 3rd 2025
Article

In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Results from the phase 1b ENGAGER-PSMA-01 trial showed deep PSA reductions and a favorable CRS profile among patients with taxane-naive CRPC.

JANX007 Displays Encouraging Safety/Efficacy in Metastatic CRPC

Roman Fabbricatore
December 2nd 2025
Article

Results from the phase 1b ENGAGER-PSMA-01 trial showed deep PSA reductions and a favorable CRS profile among patients with taxane-naive CRPC.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.

Darolutamide/ADT Improves Efficacy in Older Metastatic HSPC Population

Russ Conroy
November 23rd 2025
Article

Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.

Treatment with MCS-8 yielded no serious adverse effects among patients at a high risk of developing prostate cancer.

MCS-8, a Plant-Derived Drug, Reduces Prostate Cancer Incidence vs Placebo

Russ Conroy
November 23rd 2025
Article

Treatment with MCS-8 yielded no serious adverse effects among patients at a high risk of developing prostate cancer.